Patients with HER2-positive metastatic breast cancer treated with the novel antibody drug conjugate ARX788 conferred a significant survival benefit compared with those treated with a control. Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback